Abstract
A series of 3-[(2,4-dioxothiazolidin-5-yl)methyl]benzamide derivatives was prepared as part of a search for antidiabetic agents. A structure-activity relationship study of these compounds led to the identification of 5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxy-N-[[4-(trifluorome thyl)-phenyl]methyl]benzamide (KRP-297) as a candidate drug for the treatment of diabetes mellitus.
MeSH terms
-
Animals
-
Blood Glucose / analysis
-
Hypoglycemic Agents / chemistry*
-
Hypoglycemic Agents / pharmacology*
-
Insulin / blood
-
Mice
-
Mice, Obese
-
Pioglitazone
-
Structure-Activity Relationship
-
Thiazoles / chemistry*
-
Thiazoles / pharmacology*
-
Thiazolidinediones*
-
Thiazolidines
-
Triglycerides / blood
Substances
-
Blood Glucose
-
Hypoglycemic Agents
-
Insulin
-
Thiazoles
-
Thiazolidinediones
-
Thiazolidines
-
Triglycerides
-
5-((2,4-dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)benzamide
-
Pioglitazone